Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
TOI
$2.845
$
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
Next Earnings
2026-02-25
Beta
0.171
Average Volume
Market Cap
Last Dividend
CIK
0001799191
ISIN
US68236X1000
CUSIP
68236X100
CEO
Daniel Virnich
Sector
Healthcare
Industry
Medical - Care Facilities
Full Time Employees
825
IPO Date
2020-06-04
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Topicus.com Inc. Announces Release Date for Fourth Quarter Results | TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) announced today it intends to release its fourth quarter results on February 25, 2026. | GlobeNewsWire | 2026-02-13 19:12:00 |
| Critical Analysis: Alignment Healthcare (NASDAQ:ALHC) versus Oncology Institute (NASDAQ:TOI) | Oncology Institute (NASDAQ: TOI - Get Free Report) and Alignment Healthcare (NASDAQ: ALHC - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation. Volatility and Risk Oncology Institute has a beta | Defense World | 2026-02-10 01:46:46 |
| Contrasting Pheton (NASDAQ:PTHL) and Oncology Institute (NASDAQ:TOI) | Pheton (NASDAQ: PTHL - Get Free Report) and Oncology Institute (NASDAQ: TOI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Volatility and Risk Pheton has a beta of | Defense World | 2026-02-07 01:24:45 |
| Topicus: Recurring VMS Revenues And M&A Discipline Remain Bullish | Topicus is part of a Constellation Software spin-out. However, they still roll up European VMS firms across public and private niches. These subsidiaries remain autonomous business units, and TOITF's M&A portfolio blends TSS (over 180 companies) with the Topicus platform cluster. This is how TOITF can serve SaaS targeting education, healthcare, government, finance, legal, and other regulated verticals. | Seeking Alpha | 2026-01-25 23:37:00 |
| U.S. Neurology Associates Partners with M33 Growth to Transform Neurological Care | DALLAS and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- M33 Growth, a Boston-based venture and growth-stage investment firm, today announced its partnership with U.S. Neurology Associates (“USNA” or the “Company”), a physician services organization dedicated to transforming community-based neurology care. Through this partnership, USNA will serve neurology practices and their patients across a broad spectrum of neurological indications. Nitin Jain will serve as USNA's Chief Executive Officer and Brad Hively will serve as Chairman and co-founder. Prior to this role, Nitin Jain served as President of Value Based Care for U.S. Renal Care, and Brad Hively served as CEO of The Oncology Institute (NASDAQ: TOI). | GlobeNewsWire | 2026-01-09 16:45:00 |
| The Oncology Institute Announces Leadership Promotions | Rakesh Panda appointed Chief Information Officer Nolan Mariano appointed Chief People Officer CERRITOS, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) announced today the promotions of Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer. | GlobeNewsWire | 2026-01-09 08:00:00 |
| The Oncology Institute: Making Progress | The Oncology Institute recently achieved its first profitable Adj. EBITDA for the month and posted 37% YoY revenue growth, beating consensus by $13.9M. TOI raised FY25 guidance to $500M revenue and expects positive Adj. EBITDA in Q4, with cash flow positivity likely by mid-2026. Despite a massive share price surge in 12 months, GAAP EPS profitability remains two years away; consolidation is expected before a favorable entry point. | Seeking Alpha | 2025-12-18 15:48:49 |
| The Oncology Institute Announces Resignation of Board Member Gabe Ling | CERRITOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe Ling has resigned from the Board of Directors, effective December 1, 2025. A formal search process has been initiated to add new independent directors with complementary healthcare, clinical, and value-based care expertise. | GlobeNewsWire | 2025-12-01 08:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-23 | 2026-02-23 | View Filing |
| SC 13G | 2026-01-15 | 2026-01-15 | View Filing |
| 3 | 2026-01-12 | 2026-01-12 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| 8-K | 2026-01-07 | 2026-01-07 | View Filing |
| 4/A | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-01 | 2025-12-01 | View Filing |
| 8-K | 2025-12-01 | 2025-12-01 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-20 | 2025-11-20 | View Filing |
| 4 | 2025-11-20 | 2025-11-20 | View Filing |
| 4 | 2025-11-20 | 2025-11-20 | View Filing |
| SC 13D/A | 2025-11-20 | 2025-11-20 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 8-K | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-06 | 2025-11-06 | View Filing |
| SC 13D/A | 2025-09-05 | 2025-09-05 | View Filing |
| 4 | 2025-09-05 | 2025-09-05 | View Filing |
| 4 | 2025-08-21 | 2025-08-21 | View Filing |
| 4 | 2025-08-14 | 2025-08-14 | View Filing |
| 424B5 | 2025-08-13 | 2025-08-13 | View Filing |
| 10-Q | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| 4 | 2025-07-28 | 2025-07-28 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
| 3 | 2025-07-22 | 2025-07-22 | View Filing |
| SC 13G/A | 2025-06-24 | 2025-06-24 | View Filing |
| 4 | 2025-06-24 | 2025-06-24 | View Filing |
| 4 | 2025-06-20 | 2025-06-20 | View Filing |
| EFFECT | 2025-06-20 | 2025-06-20 | View Filing |
| S-3/A | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| S-3 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 3 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-22 | 2025-05-22 | View Filing |
| 4 | 2025-05-22 | 2025-05-22 | View Filing |
| 4 | 2025-05-22 | 2025-05-22 | View Filing |
| 4 | 2025-05-22 | 2025-05-22 | View Filing |
| 4 | 2025-05-22 | 2025-05-22 | View Filing |
| 8-K | 2025-05-19 | 2025-05-19 | View Filing |
| EFFECT | 2025-05-19 | 2025-05-19 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| 10-Q | 2025-05-14 | 2025-05-14 | View Filing |
| S-3 | 2025-05-08 | 2025-05-09 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| 8-K | 2025-05-07 | 2025-05-07 | View Filing |
| 4/A | 2025-04-28 | 2025-04-28 | View Filing |
| SC 13D/A | 2025-04-23 | 2025-04-23 | View Filing |
| D | 2025-04-08 | 2025-04-08 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| SC 13D/A | 2025-03-28 | 2025-03-28 | View Filing |
| 4 | 2025-03-28 | 2025-03-28 | View Filing |
| 4 | 2025-03-28 | 2025-03-28 | View Filing |
| 4 | 2025-03-28 | 2025-03-28 | View Filing |
| 4 | 2025-03-28 | 2025-03-28 | View Filing |
| 4 | 2025-03-28 | 2025-03-28 | View Filing |
| 4 | 2025-03-28 | 2025-03-28 | View Filing |
| 4 | 2025-03-28 | 2025-03-28 | View Filing |
| 4 | 2025-03-28 | 2025-03-28 | View Filing |
| 4 | 2025-03-28 | 2025-03-28 | View Filing |
| DEFA14A | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| DEF 14A | 2025-03-27 | 2025-03-27 | View Filing |
| ARS | 2025-03-26 | 2025-03-26 | View Filing |
| 10-K | 2025-03-26 | 2025-03-25 | View Filing |
| 8-K | 2025-03-25 | 2025-03-25 | View Filing |
| 8-K | 2025-03-24 | 2025-03-24 | View Filing |
| 8-K | 2025-03-24 | 2025-03-24 | View Filing |
| 4 | 2025-03-20 | 2025-03-20 | View Filing |
| 4 | 2025-03-20 | 2025-03-20 | View Filing |
| 4 | 2025-03-20 | 2025-03-20 | View Filing |
| PRE 14A | 2025-03-14 | 2025-03-14 | View Filing |
| 8-K | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 8-K | 2024-12-19 | 2024-12-19 | View Filing |
| SC 13G/A | 2024-12-06 | 2024-12-06 | View Filing |
| 4 | 2024-12-05 | 2024-12-05 | View Filing |
| 4 | 2024-12-02 | 2024-12-02 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Hull Moving Average Strategy | 13.26% | 0.99 | 38 | 0.45 | 0.21 | 32.33 |
| Quantum Inspired Strategy | 10.12% | 1.11 | 25 | 0.73 | 0.69 | 6.05 |
| Swarm Intelligence Strategy | 9.21% | 1.07 | 39 | 0.55 | 0.24 | 5.14 |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |